IN8bio

IN8bio INAB Stock

$0.79   -3.939024%
Add to favorites
Market Cap
$8.51M
LOW - HIGH [24H]
$0.76 - $0.82
VOLUME [24H]
$28.27K
P/E Ratio
0
Earnings per share
-$1.00
ISIN
US45674E2081
Price   Prediction

IN8bio Price Chart

Sorry, that's all we've gotfor now...

IN8bio (INAB) stock price today is 0.79 USD on Tech Market Small (-3.94% on the day). Updated .

IN8bio INAB Financial and Trading Overview

IN8bio stock price 0.79 USD
Previous Close 0.82 USD
Open 0.83 USD
Bid 1.02 USD x 200
Ask 1.77 USD x 200
Day's Range 0.72 - 0.93 USD
52 Week Range 0.72 - 2.73 USD
Volume 5.05M USD
Avg. Volume 42.38K USD
Market Cap 8.82M USD
Beta (5Y Monthly) 0.245
PE Ratio (TTM) N/A
EPS (TTM) -1 USD
Forward Dividend & Yield N/A (0%)
Ex-Dividend Date N/A
1y Target Est 7 USD

INAB Valuation Measures

Enterprise Value -2403433 USD
Trailing P/E N/A
Forward P/E -0.83265305
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) N/A
Price/Book (mrq) 0.5674548
Enterprise Value/Revenue N/A
Enterprise Value/EBITDA 0.129

Trading Information

IN8bio Stock Price History

Beta (5Y Monthly) 0.245
52-Week Change -48.42%
S&P500 52-Week Change 13.32%
52 Week High 2.73 USD
52 Week Low 0.72 USD
50-Day Moving Average 1.1 USD
200-Day Moving Average 1.39 USD

INAB Share Statistics

Avg. Volume (3 month) 42.38K USD
Avg. Daily Volume (10-Days) 31.99K USD
Shares Outstanding 10.81M
Float 8.13M
Short Ratio 0.38
% Held by Insiders 6.91%
% Held by Institutions 34.01%
Shares Short 15.73K
Short % of Float 0.18%
Short % of Shares Outstanding 0.16%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio N/A
Last Split Factor 1:30

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin 0%
Operating Margin (ttm) 0%
Gross Margin 0%
EBITDA Margin 0%

Management Effectiveness

Return on Assets (ttm) -70.33%
Return on Equity (ttm) -141.83%

Income Statement

Revenue (ttm) N/A
Revenue Per Share (ttm) N/A
Quarterly Revenue Growth (yoy) N/A
Gross Profit (ttm) N/A
EBITDA -18602000 USD
Net Income Avi to Common (ttm) -19405000 USD
Diluted EPS (ttm) -1
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 13.97M USD
Total Cash Per Share (mrq) 1.29 USD
Total Debt (mrq) 2.75M USD
Total Debt/Equity (mrq) 19.4 USD
Current Ratio (mrq) 5.782
Book Value Per Share (mrq) 1.438

Cash Flow Statement

Operating Cash Flow (ttm) -14758000 USD
Levered Free Cash Flow (ttm) -7931875 USD

Profile of IN8bio

Country United States
State NY
City New York
Address 350 5th Avenue
ZIP 10118
Phone 646 600 6438
Website https://in8bio.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 20

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company also develops INB-619, a gamma-delta TCE targeting CD19 for both oncology and autoimmune diseases; INB-300, a nsCAR-enabled DeltEx product candidates targeting difficult liquid tumors and extracranial solid tumors; INB-500, an induced pluripotent stem cell derived gamma-delta T cells that are in preclinical phase for treatment of cancer; and INB-600, a gamma-Delta T cell engager. In addition, it is developing INB-619, a gamma-delta TCE targeting CD19 for potential applications in both oncology and autoimmune diseases. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Q&A For IN8bio Stock

What is a current INAB stock price?

IN8bio INAB stock price today per share is 0.79 USD.

How to purchase IN8bio stock?

You can buy INAB shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for IN8bio?

The stock symbol or ticker of IN8bio is INAB.

Which industry does the IN8bio company belong to?

The IN8bio industry is Biotechnology.

How many shares does IN8bio have in circulation?

The max supply of IN8bio shares is 10.81M.

What is IN8bio Price to Earnings Ratio (PE Ratio)?

IN8bio PE Ratio is now.

What was IN8bio earnings per share over the trailing 12 months (TTM)?

IN8bio EPS is -1 USD over the trailing 12 months.

Which sector does the IN8bio company belong to?

The IN8bio sector is Healthcare.

IN8bio INAB included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
us US Tech Composite IXIC US 24450.37 USD —
+0.5
5.97B USD — 24225.3 USD — 24538.78 USD — — 5.97B USD —
us US Tech Global Market Composite NQGM US 1839.73 USD —
+0.22
— — 1830.2 USD — 1855.92 USD — — — —
us US Tech Health Care IXHC US 1324.83 USD —
-0.6
— — 1322.85 USD — 1342.46 USD — — — —
$2.16T
Total marketcap
$71.41B
Total volume
BTC 58.01%   •   ETH 9.87%
Dominance
Select currency